Inhaled Pirfenidone Prevented Lung Function Decline in IPF

Inhaled Pirfenidone Prevented Lung Function Decline in IPF

294983

Inhaled Pirfenidone Prevented Lung Function Decline in IPF

High-dose AP01 (inhaled pirfenidone) largely prevented lung function decline and was safe and well-tolerated during the first 24 weeks of a Phase 1/2 clinical study testing its use in patients with idiopathic pulmonary fibrosis (IPF). Avalyn Pharma, the therapy’s developer, presented the results at the 2021 International Society for Aerosols in Medicine (ISAM) Conference, held May 22–26, in Boise, Idaho. “We are pleased by the efficacy and safety profile we have seen to date with…

You must be logged in to read/download the full post.